Evidence map›Paper›PMID 31917799›Full record

ArticlePloS one2020

Evidence in support of chromosomal sex influencing plasma based metabolome vs APOE genotype influencing brain metabolome profile in humanized APOE male and female mice.

Yuan Shang, Aarti Mishra, Tian Wang, Yiwei Wang, Maunil Desai, Shuhua Chen, Zisu Mao, Loi Do, Adam S Bernstein, Theodore P Trouard and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Systematic review ofFrontiers in aging neuroscience · 2023
    Pooled it
  2. Sex differences in brain glucose metabolism and Alzheimer's disease risk and progression.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuan ShangCenter for Innovation in Brain Science, University of Arizona, Tucson, Arizona, United States of America.ORCID 0000-0002-7093-4234
Aarti MishraCenter for Innovation in Brain Science, University of Arizona, Tucson, Arizona, United States of America.
Tian WangCenter for Innovation in Brain Science, University of Arizona, Tucson, Arizona, United States of America.
Yiwei WangCenter for Innovation in Brain Science, University of Arizona, Tucson, Arizona, United States of America.ORCID 0000-0003-1836-9909
Maunil DesaiSchool of Pharmacy, University of Southern California, Los Angeles, California, United States of America.
Shuhua ChenCenter for Innovation in Brain Science, University of Arizona, Tucson, Arizona, United States of America.
Zisu MaoCenter for Innovation in Brain Science, University of Arizona, Tucson, Arizona, United States of America.
Loi DoBiomedical Engineering, University of Arizona, Tucson, Arizona, United States of America.
Adam S BernsteinCollege of Medicine, University of Arizona, Tucson, Arizona, United States of America.
Theodore P TrouardBiomedical Engineering, University of Arizona, Tucson, Arizona, United States of America.
Roberta D BrintonCenter for Innovation in Brain Science, University of Arizona, Tucson, Arizona, United States of America.
University of Arizona · USUniversity of Southern California · US

Funding

Timing of Menopausal Hormone Therapy across Perimenopause to Menopause Transition: Neuroimmune System in BrainP01AG026572 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROBERTA EILEEN BRINTON · 2006 to 2026
$53.7M
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-ADU01AG061359 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2018 to 2022
$10.0M
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal EndophenotypeR01AG057931 · NIA · UNIVERSITY OF ARIZONA · PI BRINTON, ROBERTA EILEEN, CHANG, RUI · 2018 to 2022
$6.0M
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to TreatmentRF1AG059093 · NIA · DUKE UNIVERSITY · PI BRINTON, ROBERTA EILEEN, CHANG, RUI · 2018 to 2018
$5.9M
NIA NIH HHS P01 AG026572NIA NIH HHS R01 AG057931NIA NIH HHS RF1 AG059093NIA NIH HHS U01 AG061359
6 · The paper itself

Abstract

Late onset Alzheimer's disease (LOAD) is a progressive neurodegenerative disease with four well-established risk factors: age, APOE4 genotype, female chromosomal sex, and maternal history of AD. Each risk factor impacts multiple systems, making LOAD a complex systems biology challenge. To investigate interactions between LOAD risk factors, we performed multiple scale analyses, including metabolomics, transcriptomics, brain magnetic resonance imaging (MRI), and beta-amyloid assessment, in 16 months old male and female mice with humanized human APOE3 (hAPOE3) or APOE4 (hAPOE4) genes. Metabolomic analyses indicated a sex difference in plasma profile whereas APOE genotype determined brain metabolic profile. Consistent with the brain metabolome, gene and pathway-based RNA-Seq analyses of the hippocampus indicated increased expression of fatty acid/lipid metabolism related genes and pathways in both hAPOE4 males and females. Further, female transcription of fatty acid and amino acids pathways were significantly different from males. MRI based imaging analyses indicated that in multiple white matter tracts, hAPOE4 males and females exhibited lower fractional anisotropy than their hAPOE3 counterparts, suggesting a lower level of white matter integrity in hAPOE4 mice. Consistent with the brain metabolomic and transcriptomic profile of hAPOE4 carriers, beta-amyloid generation was detectable in 16-month-old male and female brains. These data provide therapeutic targets based on chromosomal sex and APOE genotype. Collectively, these data provide a framework for developing precision medicine interventions during the prodromal phase of LOAD, when the potential to reverse, prevent and delay LOAD progression is greatest.

Indexed as

Age of OnsetAgingAlzheimer DiseaseAmyloid beta-PeptidesAnimalsApolipoprotein E4Apolipoproteins EBrainDisease Models, AnimalFemaleGenotypeHumansMagnetic Resonance ImagingMaleMetabolomeMiceAmyloid beta-PeptidesApoE protein, humanApolipoprotein E4Apolipoproteins E

Identifiers

PMID31917799
PMCPMC6952084
OpenAlexW3000396395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.